cognitive cybersecurity intelligence

News and Analysis

Search

Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up
Additional data demonstrated improved preservation of kidney function at month 3 through one year in avasopasem-treated patientsBased on ROMAN oral mucositis data,…

Source: www.marketscreener.comRead more

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts